Sign in Subscribe
Cancer research

Improved Survival Rates for Prostate Cancer Patients with PSMA PET/CT

Strategic Insights

— 2 min read

A new study from Denmark reveals that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have significantly improved survival rates compared to those who do not. The study, published in the August issue of The Journal of Nuclear Medicine, used data collected nationwide over a period of eight years and confirmed that PSMA PET/CT is a valuable tool for identifying patients who are likely to benefit from salvage radiotherapy. Researchers found that patients who underwent PSMA PET/CT before salvage radiotherapy had one-, two-, and five-year survival rates of 100, 99.5, and 98.1 percent, respectively.

Key Takeaways:

  • The study found that men with biochemically recurrent prostate cancer who underwent PSMA PET/CT before salvage radiotherapy had improved survival rates compared to those who did not.
  • The analysis revealed greater overall survival for patients who underwent PSMA PET/CT before salvage radiotherapy, with one-, two-, and five-year survival rates of 100, 99.5, and 98.1 percent, respectively.
  • Researchers used data collected nationwide over a period of eight years, confirming that PSMA PET/CT is a valuable tool for identifying patients who are likely to benefit from salvage radiotherapy.
  • The study's findings support broader use of nuclear medicine techniques to guide therapy and suggest that integrating imaging early in treatment decisions could become a new standard in cancer care.
  • Anna W. Mogensen, a PhD student at the Department of Nuclear Medicine at Aalborg University Hospital, led the study and emphasized the importance of PSMA PET/CT scans in selecting patients most likely to experience success with salvage radiotherapy.
  • The study included data from 844 patients, categorized according to whether they underwent pretreatment PSMA PET/CT (308 patients) or did not (536 patients).
  • Researchers compared the overall survival, as well as biochemical recurrence-free survival, for up to five years after completion of salvage radiotherapy.

Statistics:

  • 844 patients were included in the study, with 308 undergoing pretreatment PSMA PET/CT and 536 not undergoing the procedure.
  • The one-, two-, and five-year survival rates for PSMA PET/CT patients were 100, 99.5, and 98.1 percent, respectively.
  • The three-year biochemical recurrence-free survival rate was 74.9 percent for PSMA PET/CT patients and 69.4 percent for non-PSMA PET/CT patients.
  • The study used data collected nationwide over a period of eight years (2015-2023).
  • 40 percent of prostate cancer patients experience biochemical recurrence after radical prostatectomy.

Sources:

  • Society of Nuclear Medicine and Molecular Imaging
  • The Journal of Nuclear Medicine
  • https://jnm.snmjournals.org/
  • http://jnm.snmjournals.org
  • www.snmmi.org

Read more